You are here

Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Luxembourg, , L-2420 Luxembourg
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
17+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Have moderate to severe active rheumatoid arthritis

- Be aged of 17 years or more

- Have inadequate response to DMards

- Give written informed consent

- Physician decides to prescribe Enbrel

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT00195338
Pfizer
Completed
Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

ClinicalTrials[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg
A Post-Marketing Surveillance Looking At Safety And Adherence To Treatment Of Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg
The purpose of the study is to determine the long term safety of Enbrel in adults with active rheumatoid arthritis in Luxemburg. This is a post-marketing surveillance study in rheumatology practice patients. All patients initiated with Enbrel will be observed from the start of the study in Feb 2003 for a period of at least 5 years.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients will be included after the physician decided to prescribe Enbrel.
Rheumatoid Arthritis
Drug: etanercept
1
This is an open label, observational study.This is a post-marketing surveillance study in rheumatology practice patients in Luxemburg.Rheumatologists will be asked to document safety and adherence to therapy of Enbrel when given to adults with active rheumatoid arthritis.All patients initiated with Enbrel will be observed.
Intervention: Drug: etanercept
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
December 2010
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have moderate to severe active rheumatoid arthritis
  • Be aged of 17 years or more
  • Have inadequate response to DMards
  • Give written informed consent
  • Physician decides to prescribe Enbrel

Exclusion Criteria:

Sexes Eligible for Study: All
17 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Luxembourg
 
 
NCT00195338
0881-101343
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Innovex, Inc
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now